Tb Alternative Assets Ltd. Gilead Sciences, Inc. Transaction History

Tb Alternative Assets Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 18, 2019	SELL	$62.53 - $70.05 $2.29 Million - $2.57 Million	-36,700 Closed	0 $0
Q4 2018 Jan 17, 2019	SELL	$60.54 - $79.0 $956,532 - $1.25 Million	-15,800 Reduced 30.1%	36,700 $2.3 Million
Q3 2018 Oct 22, 2018	SELL	$71.28 - $78.92 $1.92 Million - $2.12 Million	-26,900 Reduced 33.88%	52,500 $4.05 Million
Q2 2018 Jul 20, 2018	BUY	$64.88 - $75.68 $849,927 - $991,408	13,100 Added 19.76%	79,400 $5.63 Million
Q1 2018 Apr 20, 2018	SELL	$72.84 - $88.8 $3.31 Million - $4.04 Million	-45,500 Reduced 40.7%	66,300 $5 Million
Q4 2017 Jan 25, 2018	BUY	$71.15 - $83.52 $6.52 Million - $7.65 Million	91,600 Added 453.47%	111,800 $8.01 Million
Q3 2017 Oct 17, 2017	BUY	$72.11 - $85.47 $1.46 Million - $1.73 Million	20,200	20,200 $1.64 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Tb Alternative Assets Ltd., based on Form 13F filings with the SEC.

Stay updated on Tb Alternative Assets Ltd. with notifications on news.